Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (431-440 of 583) with videos related to

Pageof 59
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Blood|December 11, 2012
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathwayYonghui Li, Li Gao, Xufeng Luo, et al.
Blood|February 15, 1996
Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemiaM R Baer, S H Bernstein, V L Brunetto, et al.
Leukemia|May 29, 2020
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 yearsAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Alice Mims, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461J C Byrd, R B Weiss, D C Arthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621Jonathan E Kolitz, Stephen L George, Richard K Dodge, et al.
Leukemia|October 10, 2015
UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETOS Goyama, J Schibler, A Gasilina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461John C Byrd, Amy S Ruppert, Krzysztof Mrózek, et al.
Blood|May 26, 1999
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experienceM Wetzler, R K Dodge, K Mrózek, et al.
American Journal of Hematology|January 31, 2017
Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantationMadlen Jentzsch, Marius Bill, Deedra Nicolet, et al.
Pageof 59

Showing results (431-440 of 583) with videos related to

Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461Guido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Blood|December 11, 2012
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathwayYonghui Li, Li Gao, Xufeng Luo, et al.
Blood|February 15, 1996
Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemiaM R Baer, S H Bernstein, V L Brunetto, et al.
Leukemia|May 29, 2020
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 yearsAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Alice Mims, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): results from Cancer and Leukemia Group B 8461J C Byrd, R B Weiss, D C Arthur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621Jonathan E Kolitz, Stephen L George, Richard K Dodge, et al.
Leukemia|October 10, 2015
UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETOS Goyama, J Schibler, A Gasilina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461John C Byrd, Amy S Ruppert, Krzysztof Mrózek, et al.
Blood|May 26, 1999
Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experienceM Wetzler, R K Dodge, K Mrózek, et al.
American Journal of Hematology|January 31, 2017
Prognostic impact of the CD34+/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantationMadlen Jentzsch, Marius Bill, Deedra Nicolet, et al.
Pageof 59